Venous Thromboembolism — Anticoagulation
Definition
Anticoagulation for venous thromboembolism (VTE — encompassing DVT and PE) requires decisions across three dimensions: (1) agent choice (which anticoagulant), (2) dose (full vs. low-intensity), and (3) duration (fixed 3–6 months vs. extended/indefinite). Direct oral anticoagulants (NOACs) are first-line over vitamin K antagonists. The two most commonly used NOACs are apixaban and rivaroxaban; until COBRRA (2026), no head-to-head RCT had directly compared them. The 3-month provoked/unprovoked binary for duration decisions is challenged by HI-PRO (2025), which shows enduring risk factors convert "provoked" VTE into a high-recurrence state requiring extended therapy.
Key Concepts
Acute-Phase NOAC Dosing (First 3 Months)
Apixaban Regimen
- 10 mg BID × 7 days → 5 mg BID thereafter
- Higher initial dose over only 7 days (shorter loading vs rivaroxaban)
Rivaroxaban Regimen
- 15 mg BID × 21 days → 20 mg once daily thereafter
- Higher loading dose for 21 days; 50% above maintenance dose
- Loading phase associated with higher early bleeding risk (COBRRA)
NOAC Choice — Apixaban vs Rivaroxaban: COBRRA Trial
(sources/NOAC-VTE-COBRRA-NEJM-2026, rating: very high)
The COBRRA trial (n=2,760; PROBE design; 32 centres; Canada/Australia/Ireland; 3-month follow-up) is the first head-to-head RCT comparing apixaban vs rivaroxaban in acute VTE:
| Outcome | Apixaban | Rivaroxaban | RR (95% CI) | P |
|---|---|---|---|---|
| Clinically relevant bleeding | 3.3% | 7.1% | 0.46 (0.33–0.65) | <0.001 |
| Major bleeding | 0.4% | 2.4% | 0.16 (0.06–0.40) | — |
| CRNMB | 2.9% | 4.9% | 0.59 (0.40–0.86) | — |
| Recurrent VTE | 1.1% | 1.0% | 1.08 (0.52–2.23) | NS |
| All-cause death | 0.1% | 0.3% | 0.25 (0.03–2.26) | NS |
- Bleeding difference consistent across all prespecified subgroups
- Most bleeding difference occurs in first 21 days — correlates with rivaroxaban's higher loading dose period
- Medication adherence paradoxically lower with apixaban (65.7% vs 75.1%), yet VTE recurrence identical — the twice-daily dosing of apixaban may reduce adherence without affecting efficacy
- Excluded: active cancer, CrCl <30, weight >120 kg, AF
Duration of Anticoagulation — The Provoked/Unprovoked Binary
Standard Guidance
- Provoked VTE (surgery, trauma, immobility): 3 months anticoagulation; low recurrence risk (~2–3%/year) after stopping → no extended therapy in guidelines
- Unprovoked VTE: High recurrence risk (~6–10%/year) → extended/indefinite anticoagulation recommended
The HI-PRO Challenge to the Binary
(sources/Apixaban-VTE-HIPRO-NEJM-2025, rating: high)
HI-PRO (n=600; double-blind; Brigham and Women's Hospital; 12-month extension after ≥3 months standard treatment) tested apixaban 2.5 mg BID vs placebo in patients with provoked VTE + ≥1 enduring risk factor:
| Outcome | Apixaban 2.5 mg BID | Placebo | HR (95% CI) | P |
|---|---|---|---|---|
| Recurrent VTE | 1.3% | 10.0% | 0.13 (0.04–0.36) | <0.001 |
| Major bleeding | 0.3% | 0% | — | NS |
| CRNMB | 4.8% | 1.7% | 2.68 (0.96–7.43) | 0.06 |
| All-cause death | 0.3% | 1.0% | — | NS |
Key finding: The 10% placebo recurrence rate in "provoked" VTE patients with enduring risk factors equals or exceeds the ~6–10%/year threshold used to justify indefinite anticoagulation in unprovoked VTE. Enduring risk factors tested: obesity (BMI ≥30), chronic inflammatory/autoimmune disorder, chronic lung disease, ASCVD.
- 87% relative risk reduction in VTE recurrence
- Very low major bleeding risk (1 event: minor subdural haematoma, no clinical consequence)
- CRNMB trend (HR 2.68; P=0.06): clinically meaningful but trial underpowered for this endpoint; absolute rate 4.8% — nuanced risk-benefit, especially since all recurrent VTEs were nonfatal
- Consistent benefit across major vs minor transient provoking factors (post hoc)
Extended-Phase Dosing Options (After ≥3 Months)
- Apixaban 2.5 mg BID — validated in AMPLIFY-EXT (unprovoked VTE) and HI-PRO (provoked + enduring risk)
- Rivaroxaban 10 mg OD — validated in EINSTEIN-CHOICE (unprovoked VTE; Einstein-Choice also showed rivaroxaban 10 mg OD superior to aspirin for recurrence)
- Apixaban 5 mg BID (full dose) vs 2.5 mg BID (reduced dose): API-CAT (NEJM 2025) showed 2.5 mg BID noninferior for VTE recurrence with superior bleeding in cancer-associated VTE (see concepts/Cancer-Associated-VTE)
Risk Stratification for Extended Duration
- VTE-PREDICT score (Eur Heart J 2023): integrates clinical variables to estimate VTE recurrence and bleeding risk on extended anticoagulation; assists shared decision-making
- Polygenic risk scores and AI — emerging tools, not yet validated for routine clinical use (referenced in HI-PRO)
- Enduring risk factors as a practical clinical trigger for extended therapy in provoked VTE: obesity, autoimmune disease, chronic lung disease, ASCVD
Anticoagulation Exclusions Common to Both Trials
- Active cancer (separate management, see concepts/Cancer-Associated-VTE)
- Atrial fibrillation (separate indication, different dosing)
- CrCl <30 ml/min (renal impairment requiring dose adjustment)
Contradictions / Open Questions
- COBRRA: mechanism of bleeding difference unexplained — whether the rivaroxaban loading-dose hypothesis is correct requires a trial comparing rivaroxaban 10 mg OD (extended dose) vs apixaban in the acute phase; pharmacodynamic differences between the two factor Xa inhibitors cannot be excluded. (sources/NOAC-VTE-COBRRA-NEJM-2026)
- COBRRA: adherence paradox — apixaban adherence 65.7% vs rivaroxaban 75.1%, yet VTE recurrence identical (1.1% vs 1.0%); raises questions about whether subtherapeutic adherence in the apixaban arm underestimates its true efficacy advantage. (sources/NOAC-VTE-COBRRA-NEJM-2026)
- HI-PRO: CRNMB signal (HR 2.68; P=0.06) — trial not powered for this endpoint; whether the ~3% absolute excess in CRNMB with apixaban outweighs the 8.7% absolute reduction in recurrent VTE depends on patient values and clinical context. (sources/Apixaban-VTE-HIPRO-NEJM-2025)
- HI-PRO: single-center limitation — generalizability to diverse health systems uncertain. (sources/Apixaban-VTE-HIPRO-NEJM-2025)
- Duration beyond 12 months in provoked + enduring risk: HI-PRO only covers 12 months of extended treatment; no data exist on whether anticoagulation should continue indefinitely or can be safely stopped
- Which enduring risk factors matter most: HI-PRO enrolled a heterogeneous enduring-risk population (obesity, autoimmune, lung disease, ASCVD); subgroup analyses were underpowered; it is unknown whether all confer equivalent recurrence risk
- Aspirin co-administration: ~20% of HI-PRO patients were on low-dose aspirin; discontinuation may reduce CRNMB without affecting VTE protection
Connections
- Related to concepts/Cancer-Associated-VTE — cancer VTE excluded from both trials; has separate DOAC evidence (API-CAT, Caravaggio)
- Related to concepts/Acute-PE-Clinical-Categories — acute management precedes anticoagulation choice decisions
- Related to concepts/Pulmonary-Hypertension — chronic thromboembolic PH as long-term sequela of VTE (CTEPH)
Sources
- sources/NOAC-VTE-COBRRA-NEJM-2026 — head-to-head apixaban vs rivaroxaban bleeding RCT (very high)
- sources/Apixaban-VTE-HIPRO-NEJM-2025 — extended apixaban in provoked VTE + enduring risk (high)